Comparison · NCT04414618-eae1c5bf
Opaganib vs Placebo: Evaluation of Mortality 30 Days Post-baseline
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Opaganib vs Placebo: Evaluation of Mortality 30 Days Post-baseline. Trial comparisons, record NCT04414618-eae1c5bf. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04414618-eae1c5bf
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.136 | 0.0475 | 0.333 | wilson | |
| Risk in group 2 | 0.111 | 0.031 | 0.328 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0253 | -0.209 | 0.238 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.23 | 0.229 | 6.57 | log | |
| Odds ratio, group 1 over group 2 | 1.26 | 0.187 | 8.52 | log | |
| Number needed to treat, for one more participant with the outcome on Opaganib than on Placebo | 39.6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Opaganib | Study participants received opaganib 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours (pharmacological and/or supportive). | 3 | 22 | OG000 |
| Group 2 | Placebo | Study participants received placebo 2 x 250 mg capsules (500 mg) plus standard of care every 12 hours (pharmacological and/or supportive). | 2 | 18 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Evaluation of Mortality 30 Days Post-baseline
- Description
- The mortality in each arm 30 days post-baseline.
- Time frame
- 30 days after day 1 of treatment
- Population
- Modified ITT (mITT) population (randomized and treated with at least one dose of study medication).
Source ClinicalTrials.gov
Trial
- Title
- A Study of Opaganib in Coronavirus Disease 2019 Pneumonia
- NCT number
- NCT04414618
- Phases
- PHASE2
- Conditions
- Coronavirus Infections
- Interventions
- Opaganib, Placebo
- Lead sponsor
- RedHill Biopharma Limited
- Results first posted
- 2022-03-21
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04414618?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04414618-eae1c5bf